复宏汉霖是一家国际化创新生物制药公司，产品覆盖肿瘤、自免、眼科疾病等领域。自2010 年成立以来，复宏汉霖已建成一体化生物制药平台，高效创新的自主核心能力贯穿研发、生产及商业运营全产业链。HLX43：具备全球BIC 潜力的PD-L1 ADC 资产。HLX43 是全球第二款、国内首款进入临床的PD-L1 ADC，通过泛瘤种靶点PD-L1 的核心骨架HLX20 单抗+宜联TMALIN 技术平台开发策略...
Source Link复宏汉霖是一家国际化创新生物制药公司，产品覆盖肿瘤、自免、眼科疾病等领域。自2010 年成立以来，复宏汉霖已建成一体化生物制药平台，高效创新的自主核心能力贯穿研发、生产及商业运营全产业链。HLX43：具备全球BIC 潜力的PD-L1 ADC 资产。HLX43 是全球第二款、国内首款进入临床的PD-L1 ADC，通过泛瘤种靶点PD-L1 的核心骨架HLX20 单抗+宜联TMALIN 技术平台开发策略...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.